BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//ZContent.net//ZapCalLib 1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
SUMMARY:Design of Norketamine Prodrugs for Treatment of Major Depressive Di
 sorder
LOCATION:Virtual - Zoom
TZID:America/Denver
DTSTART:20230327T160000
UID:2026-04-24-08-31-45@natsci.colostate.edu
DTSTAMP:20260424T083145
Description:About the Seminar\n\nKetamine has become a promising new therap
 eutic for treatment-resistant major depression. However\, the transient na
 ture of ketamine’s anti-depressive activity reduces its current viabilit
 y as a treatment. Additionally\, since the drug has such a high incidence 
 of abuse\, receiving treatment is challenging for patients. The drug Vyvan
 se is a prime example of how medicinal chemists have addressed many of the
  issues that ketamine also faces. By attaching a lysine amino acid residue
  to Adderall\, Vyvanse is slowly metabolized into Adderall by proteases in
  the blood (Figure 1A). This lowers the ability for the drug to be abused 
 and eliminates the need for multiple doses throughout the day. Ketamine al
 so has an amine that could be used to make a prodrug. Previous reports in 
 the patent literature have utilized (acyloxy)alkyl carbamate ketamine prod
 rugs in the hopes of achieving a slow release similar to Vyvanse (Figure 1
 B). However\, while these prodrugs do display an increase in bioavailabili
 ty (Cmax)\, they do not have any significant extended-release characterist
 ics (Tmax and T1/2 roughly equal for prodrugs and ketamine). To address th
 e current limitations\, this proposal will focus on the ketamine metabolit
 e norketamine as a scaffold for prodrug design.\n\n 4:00 pm
END:VEVENT
END:VCALENDAR